文献速递泌尿与男性生殖病理

前列腺穿刺活检筛状癌观察者间可重复性及ISUP标准验证

Interobserver reproducibility of cribriform cancer in prostate needle biopsies and validation of International Society of Urological Pathology criteria.
PubMed 文献 · Histopathology · 2023-01-25

九名前列腺病理专家依据ISUP标准独立复阅304例数字化穿刺活检,筛状与非筛状癌的2/3共识诊断率达90%(272/304),平均kappa值0.56(95%CI 0.52-0.61)。每层面>2个筛状结构、最大筛状团块≥9个腔或直径≥0.5 mm可高比例预测共识诊断。

要点

  • 筛状癌共识诊断率90%,平均kappa 0.56提示中等可重复性。
  • Gleason 7(3+4)、7(4+3)、8、9-10中筛状癌共识患病率分别为4%、12%、21%、20%。
  • 每层面>2个筛状结构、最大团块≥9腔或直径≥0.5 mm可预测共识诊断。

核心结论

  • 筛状前列腺癌见于少数高级别癌穿刺活检,严格诊断标准可识别筛状结构并生成共识集供标准化。

研究设计与样本

  • 九名来自五大洲的前列腺病理专家独立复阅304例数字化穿刺活检,依据近期ISUP标准判断筛状癌。
  • 活检来自702例系列穿刺中由一名专家复阅富集的高级别癌及潜在筛状结构病例。

主要发现

  • 筛状与非筛状癌的2/3共识诊断率达90%(272/304),平均kappa值0.56(95%CI 0.52-0.61)。
  • 共识筛状癌患病率在Gleason 7(3+4)、7(4+3)、8、9-10中分别为4%、12%、21%、20%。
  • 每层面>2个筛状结构预测共识筛状癌88%(70/80),非筛状癌3%(2/80)(P<0.01)。
  • 最大筛状团块≥9个腔预测共识筛状癌84%(87/103),非筛状癌5%(5/103)(P<0.01)。
  • 最大筛状团块直径≥0.5 mm预测共识筛状癌90%(56/62),非筛状癌2%(1/62)(P<0.01)。

关键数值与推荐

  • 共识诊断采用2/3专家一致意见定义筛状与非筛状癌。
  • 每层面>2个筛状结构、最大筛状团块≥9个腔或直径≥0.5 mm为预测共识诊断的候选标准。

临床怎么用

  • 病理医生可参考每层面>2个筛状结构、最大团块≥9腔或直径≥0.5 mm等标准辅助识别筛状癌。
  • 筛状癌在高级别穿刺活检中占少数,诊断时需注意观察者间可重复性为中等(kappa 0.56)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: There is strong evidence that cribriform morphology indicates a worse prognosis of prostatic adenocarcinoma. Our aim was to investigate its interobserver reproducibility in prostate needle biopsies. METHODS AND RESULTS: A panel of nine prostate pathology experts from five continents independently reviewed 304 digitised biopsies for cribriform cancer according to recent International Society of Urological Pathology criteria. The biopsies were collected from a series of 702 biopsies that were reviewed by one of the panellists for enrichment of high-grade cancer and potentially cribriform structures. A 2/3 consensus diagnosis of cribriform and noncribriform cancer was reached in 90% (272/304) of the biopsies with a mean kappa value of 0.56 (95% confidence interval 0.52-0.61). The prevalence of consensus cribriform cancers was estimated to 4%, 12%, 21%, and 20% of Gleason scores 7 (3 + 4), 7 (4 + 3), 8, and 9-10, respectively. More than two cribriform structures per level or a largest cribriform mass with ≥9 lumina or a diameter of ≥0.5 mm predicted a consensus diagnosis of cribriform cancer in 88% (70/80), 84% (87/103), and 90% (56/62), respectively, and noncribriform cancer in 3% (2/80), 5% (5/103), and 2% (1/62), respectively (all P < 0.01). CONCLUSION: Cribriform prostate cancer was seen in a minority of needle biopsies with high-grade cancer. Stringent diagnostic criteria enabled the identification of cribriform patterns and the generation of a large set of consensus cases for standardisation.

来源:Histopathology,查看原文。版权归原作者所有。

引用

  1. Egevad L, Delahunt B, Iczkowski KA, et al. Interobserver reproducibility of cribriform cancer in prostate needle biopsies and validation of International Society of Urological Pathology criteria. Histopathology. 2023. PMID: 36645163. doi:10.1111/his.14867

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。